Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

1.

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP, Sandmaier BM, Sorror M, Stirewalt DL, Wilson WA, Storb R, Appelbaum FR, Gooley T.

Blood. 2012 Aug 16;120(7):1398-408. doi: 10.1182/blood-2012-04-423046. Epub 2012 Jul 5.

PMID:
22767498
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA.

Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015.

PMID:
19167680
[PubMed - indexed for MEDLINE]
3.

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, Sandmaier BM, Witherspoon RP, Nash RA, Sanders JE, Bedalov A, Hansen JA, Clurman BE, Storb R, Appelbaum FR, Deeg HJ.

Blood. 2007 Aug 15;110(4):1379-87. Epub 2007 May 8.

PMID:
17488876
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

PMID:
19135940
[PubMed - indexed for MEDLINE]
5.

Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.

Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M.

J Exp Clin Cancer Res. 2011 Apr 10;30:36. doi: 10.1186/1756-9966-30-36.

PMID:
21477348
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.

Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers ME, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelhaum FR.

Biol Blood Marrow Transplant. 2002;8(3):161-9.

PMID:
11939606
[PubMed - indexed for MEDLINE]
7.

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR.

Blood. 2002 Aug 15;100(4):1201-7.

PMID:
12149198
[PubMed - indexed for MEDLINE]
Free Article
8.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF.

Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55. doi: 10.1016/j.bbmt.2007.11.012.

PMID:
18215785
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo.

Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20.

PMID:
24558201
[PubMed - indexed for MEDLINE]
10.

Transplantation for myelodysplastic syndromes 2013.

Vaughn JE, Scott BL, Deeg HJ.

Curr Opin Hematol. 2013 Nov;20(6):494-500. doi: 10.1097/MOH.0b013e328364f547. Review.

PMID:
24104409
[PubMed - indexed for MEDLINE]
11.

Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.

Scott BL, Storer BE, Greene JE, Hackman RC, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2007 Mar;13(3):345-54.

PMID:
17317588
[PubMed - indexed for MEDLINE]
12.

[Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].

Wei J, Chen Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):305-11. Chinese.

PMID:
18426654
[PubMed - indexed for MEDLINE]
13.

Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.

Ayas M, Saber W, Davies SM, Harris RE, Hale GA, Socie G, LeRademacher J, Thakar M, Deeg HJ, Al-Seraihy A, Battiwalla M, Camitta BM, Olsson R, Bajwa RS, Bonfim CM, Pasquini R, Macmillan ML, George B, Copelan EA, Wirk B, Al Jefri A, Fasth AL, Guinan EC, Horn BN, Lewis VA, Slavin S, Stepensky P, Bierings M, Gale RP.

J Clin Oncol. 2013 May 1;31(13):1669-76. doi: 10.1200/JCO.2012.45.9719. Epub 2013 Apr 1.

PMID:
23547077
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT).

Haematologica. 2009 Apr;94(4):542-9. doi: 10.3324/haematol.2008.000927. Epub 2009 Mar 10.

PMID:
19278968
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.

PMID:
22331955
[PubMed - indexed for MEDLINE]
Free Article
16.

Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.

Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, Carrillo E, Martino ML, Montero I, González J, Parody R, Espigado I, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):144-52. doi: 10.1016/j.clml.2012.09.013. Epub 2012 Nov 6.

PMID:
23137720
[PubMed - indexed for MEDLINE]
17.

Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos EB.

Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44.

PMID:
17241929
[PubMed - indexed for MEDLINE]
18.

Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia.

Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D.

Biol Blood Marrow Transplant. 2011 Mar;17(3):356-64. doi: 10.1016/j.bbmt.2010.05.012. Epub 2010 May 27.

PMID:
20553926
[PubMed - indexed for MEDLINE]
19.

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.

Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group.

Blood. 2012 Jan 12;119(2):551-8. doi: 10.1182/blood-2011-07-367508. Epub 2011 Nov 16.

PMID:
22096250
[PubMed - indexed for MEDLINE]
Free Article
20.

Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.

Scott B, Deeg HJ, Storer B, Chauncey T, Petersdorf S, Slattery J, Appelbaum F.

Leuk Lymphoma. 2004 Dec;45(12):2409-17.

PMID:
15621753
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk